Niu Zhang Ming, CEO of De Rui Zhi Pharmaceutical, said that AI helped shorten the drug development cycle by half and reduce pre-clinical and clinical costs. The Chinese biotech startup expects to launch a “major” drug by 2028 and 2029, and plans to launch it next year. The company is seeking an authorization agreement for the AI-assisted design of the experimental GLP-1 drug MDR-001, and is expected to announce the relevant agreement within the next 12 months.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.